Health ❯Healthcare ❯Alzheimer's Disease

Treatment Options

Donanemab Lecanemab Efficacy of Lecanemab Eli Lilly's Donanemab Clinical Research Clinical Trials

EU Regulators Reject Eli Lilly's Alzheimer's Drug Over Safety Concerns

The European Medicines Agency cites risks of brain swelling and bleeding, prompting Eli Lilly to seek re-examination of the decision.

Cassava Sciences Halts Alzheimer’s Drug Trials Following Phase 3 Failure

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs